Register for our free email digests:
Latest From North China Pharmaceutical Group Corp.
The start of the fiscal second half in Japan in October brought a flurry of executive changes and reorganizations at foreign and domestic firms in the country including Allergan, Sandoz and Takeda.
Two recently released inspection results by western pharmaceutical regulatory authorities have put GlaxoSmithKline PLC and Pfizer Inc. in the spotlight after both multinationals ran into manufacturing problems in China.
China is facing a serious shortage of recombinant hepatitis B vaccines because three major domestic manufacturers – Dalian-based Hissen, Shenzhen-based Bio Kangtai and Tiantan Biological Products of Beijing– officially halted production of their products on 1 January.
Orchid Chemicals and Pharmaceuticals' recent exit from its 50:50 manufacturing joint venture in China does not imply that it is moving out of the Chinese market, the Indian company has affirmed. Orchid's plans are seen rather as part of the firm's strategy to consolidate manufacturing operations in India.
- Therapeutic Areas
- Neurology, Nervous System
- Addex Pharmaceuticals Ltd.
- Western Europe
- Parent & Subsidiaries
- Addex Therapeutics
- Senior Management
Tim Dyer, CEO
Roger G Mills, MD, CMO
Sonia Poli, PhD, CSO & Head, Dev.
- Contact Info
Phone: (41) 22 884 1555
12, chemin des Aulx
Plan-les-Ouates, Geneva, 1228
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.